# Metabolic Research Compounds

## Metabolic Research Compounds

This page indexes the compounds in our catalogue that appear in the metabolic and energy-balance research literature, organised by mechanism. It is a reference to what each compound is and what has been studied. It is not guidance for use, and no combination, sequence or quantity is recommended here.

### Incretin Receptor Agonists

This class acts at receptors involved in glucose-dependent insulin secretion and gastric motility. Published data in this class is reported as changes in body weight and glycaemic markers within enrolled, supervised human trial populations. Those are trial observations under clinical monitoring and should not be read as a description of what these materials do outside that setting.

- **[Semaglutide](https://portaltowellness.net/shop/semaglutide/)** — a GLP-1 receptor agonist, and the most extensively published compound in the class. Background: [Semaglutide Research Guide](https://portaltowellness.net/research/semaglutide-research-guide/) .
- **[Tirzepatide](https://portaltowellness.net/shop/tirzepatide-60mg/)** — a dual GIP/GLP-1 receptor agonist. Background: [Tirzepatide Research Guide](https://portaltowellness.net/research/tirzepatide-research-guide/) .
- **Retatrutide** — a triple GLP-1/GIP/glucagon receptor agonist. Phase 3 TRIUMPH results were reported during 2026; it remains an investigational compound with no approved regulatory status in any jurisdiction.
- **[Cagrilintide](https://portaltowellness.net/shop/cagrilintide/)** — an amylin analogue, studied at a receptor system distinct from the incretin pathway.

### Mitochondrial and Cofactor Compounds

- **[NAD⁺](https://portaltowellness.net/shop/mitochondrial-energy-bundle/)** — a coenzyme central to redox reactions, mitochondrial electron transport, and sirtuin and PARP enzyme activity. Background: [NAD+ research](https://portaltowellness.net/research/nad-plus-benefits-research/) and the [mitochondrial compound comparison](https://portaltowellness.net/research/mitochondrial-peptide-comparison-ss31-mots-c-nad/) .
- **[Vitamin B12 (methylcobalamin)](https://portaltowellness.net/shop/vitamin-b12/)** — a cofactor in the methionine synthase and methylmalonyl-CoA mutase reactions.

### Adjacent Research Compounds

- **[BPC-157](https://portaltowellness.net/shop/bpc-157-tb-500-injectable/)** — a pentadecapeptide studied largely in rodent gastrointestinal and soft-tissue models. Direct human administration data is limited. See [the preclinical review](https://portaltowellness.net/research/bpc-157-preclinical-research/) and [recovery peptide evidence gaps](https://portaltowellness.net/research/recovery-peptide-evidence-gaps/) .

### A Note on Evidence Stage

These compounds sit at very different evidence stages, and listing them on one page does not imply they are comparably well studied. The incretin agonists have large randomised human trial programmes behind them; several of the other compounds have no controlled human data at all. The [Research Library](https://portaltowellness.net/research/) states the evidence stage for each compound individually.

**Research use only.** All compounds referenced on this page are supplied for laboratory research use only. They are not drugs, foods or cosmetics, and are not for human or veterinary use. Nothing on this page is a therapeutic claim, and no diagnosis, treatment, cure or prevention of any condition is stated or implied.

---

Source: https://portaltowellness.net/metabolic-kit/
Research use only. Terms: https://portaltowellness.net/research-use-only/